Tags

Type your tag names separated by a space and hit enter

The epidemiology and disease outcomes of human T-lymphotropic virus type II.
AIDS Rev. 2004 Jul-Sep; 6(3):144-54.AR

Abstract

Human T-lymphotropic virus type II (HTLV-II) is a human retrovirus which is endemic in Amerindian and pygmy tribes. Molecular subtypes show geographic segregation consistent with an ancient origin of this virus within humans in Africa or South America. More recently, injection drug users in the United States and Europe have become infected with HTLV-II, and secondary sexual transmission has introduced the virus at low levels into the general population and blood donors. HTLV-II has been linked with a spastic paraparesis called HTLV-associated myelopathy / tropical spastic paraparesis (HAM/TSP), and perhaps with other neurological syndromes. It is also associated with an increased incidence of pneumonia and bronchitis, inflammatory conditions such as arthritis, and perhaps with increased mortality. Except for a few cases of cutaneous lymphoma in patients coinfected with HIV, there is no evidence that HTLV-II causes lymphoproliferative disease. HTLV-II and HIV coinfection has not been proven to alter the course of HIV disease, but such patients may have altered levels of CD4+ and CD8+ lymphocytes, and antiretroviral therapy may paradoxically increase HTLV-II proviral load.

Authors+Show Affiliations

Blood Systems Research Institute, San Francisco, CA 94118, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

15595431

Citation

Roucoux, Diana F., and Edward L. Murphy. "The Epidemiology and Disease Outcomes of Human T-lymphotropic Virus Type II." AIDS Reviews, vol. 6, no. 3, 2004, pp. 144-54.
Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004;6(3):144-54.
Roucoux, D. F., & Murphy, E. L. (2004). The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Reviews, 6(3), 144-54.
Roucoux DF, Murphy EL. The Epidemiology and Disease Outcomes of Human T-lymphotropic Virus Type II. AIDS Rev. 2004 Jul-Sep;6(3):144-54. PubMed PMID: 15595431.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The epidemiology and disease outcomes of human T-lymphotropic virus type II. AU - Roucoux,Diana F, AU - Murphy,Edward L, PY - 2004/12/15/pubmed PY - 2005/2/11/medline PY - 2004/12/15/entrez SP - 144 EP - 54 JF - AIDS reviews JO - AIDS Rev VL - 6 IS - 3 N2 - Human T-lymphotropic virus type II (HTLV-II) is a human retrovirus which is endemic in Amerindian and pygmy tribes. Molecular subtypes show geographic segregation consistent with an ancient origin of this virus within humans in Africa or South America. More recently, injection drug users in the United States and Europe have become infected with HTLV-II, and secondary sexual transmission has introduced the virus at low levels into the general population and blood donors. HTLV-II has been linked with a spastic paraparesis called HTLV-associated myelopathy / tropical spastic paraparesis (HAM/TSP), and perhaps with other neurological syndromes. It is also associated with an increased incidence of pneumonia and bronchitis, inflammatory conditions such as arthritis, and perhaps with increased mortality. Except for a few cases of cutaneous lymphoma in patients coinfected with HIV, there is no evidence that HTLV-II causes lymphoproliferative disease. HTLV-II and HIV coinfection has not been proven to alter the course of HIV disease, but such patients may have altered levels of CD4+ and CD8+ lymphocytes, and antiretroviral therapy may paradoxically increase HTLV-II proviral load. SN - 1139-6121 UR - https://www.unboundmedicine.com/medline/citation/15595431/The_epidemiology_and_disease_outcomes_of_human_T_lymphotropic_virus_type_II_ L2 - http://hivinsite.ucsf.edu/InSite?page=kb-05-02-01 DB - PRIME DP - Unbound Medicine ER -